RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia
Open Access
- 30 March 2022
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 36 (5) , 1237-1252
Abstract
Despite recent advances in acute myeloid leukemia (AML) molecular characterization and targeted therapies, a majority of AML cases still lack therapeutically actionable targets. In 127 AML cases with unmet therapeutic needs, as defined by the exclusion of ELN favorable cases and of FLT3-ITD mutations, we identified 51 (40%) cases with alterations in RAS pathway genes (RAS+, mostly NF1, NRAS, KRAS, and PTPN11 genes). In 79 homogeneously treated AML patients from this cohort, RAS+ status were associated with higher white blood cell count, higher LDH, and reduced survival. In AML models of oncogenic addiction to RAS-MEK signaling, the MEK inhibitor trametinib demonstrated antileukemic activity in vitro and in vivo. However, the efficacy of trametinib was heterogeneous in ex vivo cultures of primary RAS+ AML patient specimens. From repurposing drug screens in RAS-activated AML cells, we identified pyrvinium pamoate, an anti-helminthic agent efficiently inhibiting the growth of RAS+ primary AML cells ex vivo, preferentially in trametinib-resistant PTPN11- or KRAS-mutated samples. Metabolic and genetic complementarity between trametinib and pyrvinium pamoate translated into anti-AML synergy in vitro. Moreover, this combination inhibited the propagation of RA+ AML cells in vivo in mice, indicating a potential for future clinical development of this strategy in AML.Keywords
This publication has 67 references indexed in Scilit:
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respirationFrontiers in Oncology, 2012
- Small-molecule inhibition of Wnt signaling through activation of casein kinase 1αNature Chemical Biology, 2010
- A Versatile Viral System for Expression and Depletion of Proteins in Mammalian CellsPLOS ONE, 2009
- Ba/F3 cells and their use in kinase drug discoveryCurrent Opinion in Oncology, 2007
- Implications of NRAS mutations in AML: a study of 2502 patientsBlood, 2006
- NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogénétique HématologiqueLeukemia, 2006
- RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 yearsBlood, 2005
- Antileukemic activity of rapamycin in acute myeloid leukemiaBlood, 2005
- Prognostically Useful Gene-Expression Profiles in Acute Myeloid LeukemiaNew England Journal of Medicine, 2004